A therapeutic monoclonal antibody against cytotoxic T-lymphocyte-associated antigen 4, which prolongs overall survival in patients with advanced melanoma. It may also be effective for managing advanced non-small cell carcinoma of lung and metastatic hormone-refractory prostate cancer.
Adverse effects Stomach pain, bloating, constipation, diarrhoea, fever, dyspnoea, dysuria; potentially fatal immune reactions due to T cell activation.
Other names MDX101, MDX110, Yervoy
Reference NEJM 2013; 369:122-133